FierceBiotechOriginal article
{"a":[{"_":"J&J’s Contineum-partnered depression drug flunks another phase 2 test","$":{"href":"/biotech/jjs-contineum-partnered-asset-flunks-another-phase-2-test","hreflang":"en"}}]}
Phase 2negativeJNJ-5120Negative
AI Analysis
Summary
Johnson & Johnson's JNJ-5120, a depression drug developed in partnership with Contineum Therapeutics, failed to meet its primary endpoint in a Phase 2 trial. The negative data outcome diminishes the clinical prospects for this asset.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
missed primary endpoint
Importance:6/10
Sentiment:
-0.85
Phase 2 failuredepressionclinical trialpartnership
Related Companies
Read the original article
Published by FierceBiotech on September 15, 2026 4:08 AM